Latest studies
- Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaBosnia and Herzegovina - Active not recruitingPHASE3
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
This study looks at a new medicine called concizumab for people with haemophilia A or B without inhibitors. It aims to see how well it prevents bleeding and if it's safe. Participants will take the medicine daily, usually by injection under the skin, for up to 8 years.
Haemophilia A Without InhibitorsHaemophilia B Without InhibitorsBosnia and Herzegovina - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
This study compares a new drug, Giredestrant, with standard hormone therapy for early breast cancer. It's for people with a specific type of breast cancer (ER-positive, HER2-negative) who have already had surgery.
Early Breast CancerBosnia and Herzegovina - Active not recruitingPHASE3
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
This study is testing a new medicine, concizumab, for people with haemophilia A or B, with or without 'inhibitors'. It aims to see if concizumab can prevent bleeds and if it's safe to use. Participants will inject the medicine daily under their skin.
Haemophilia A and B With and Without InhibitorsBosnia and Herzegovina - Active not recruitingPHASE3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
This study looks at a new medicine called ziltivekimab for people with heart failure and inflammation. It aims to see if monthly injections of ziltivekimab can help, compared to a dummy medicine, over a few years.
Heart FailureBosnia and Herzegovina - RecruitingPHASE2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is testing a new medicine, Imeroprubart, for adults with a nerve condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Researchers want to see if it's safe and helps improve symptoms compared to a dummy treatment.
Chronic Inflammatory Demyelinating PolyneuropathyBosnia and Herzegovina - RecruitingPHASE2
Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
This study looks at a new, climate-friendly asthma inhaler. We want to check if it works just as well and is as safe as current inhalers for people with mild to moderate asthma. It's about finding better ways to manage asthma while caring for our planet.
AsthmaBosnia and Herzegovina - Recruiting
SCAD : a Registry of Spontaneous Coronary Artery Dissection
This study is gathering information on a heart condition called Spontaneous Coronary Artery Dissection (SCAD). It's looking at how doctors currently diagnose and treat SCAD across Europe to learn more about it and improve care for patients.
Spontaneous Coronary Artery DissectionBosnia and Herzegovina - Active not recruitingPHASE3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
This study looks at a new drug, pacritinib, for people with myelofibrosis and very low platelet counts. It compares pacritinib to other standard treatments decided by your doctor, to see if it can help improve symptoms.
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia MyelofibrosisBosnia and Herzegovina - Enrolling by invitation
EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV
The EuroSIDA study looks at how HIV affects people in Europe and how treatments work over time. It helps us understand health changes and the impact of new medicines for HIV and related conditions like hepatitis.
HIVHepatitis BHepatitis CAIDSBosnia and Herzegovina - Active not recruitingPHASE3
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
This study compares a new medicine, risankizumab, with a dummy treatment (placebo) for people with active psoriatic arthritis. It checks how safe and effective risankizumab is, especially for those who haven't responded well to other treatments.
Psoriatic ArthritisBosnia and Herzegovina - Active not recruitingPHASE3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called lutikizumab for people aged 12 and over with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy treatment (placebo) to see if it helps reduce HS symptoms and is safe.
Hidradenitis SuppurativaBosnia and Herzegovina - Active not recruiting
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
This study looks at how well a medicine called Humira works and how safe it is for children aged 6 to 17 with Crohn's disease. It also compares Humira to other common treatments like azathioprine, 6-mercaptopurine, or methotrexate, watching patients over a long time.
Crohn's DiseaseBosnia and Herzegovina - Active not recruitingPHASE3
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
This study looks at a new tablet treatment, upadacitinib, for adults with moderate to severe lupus. It checks how safe and effective the medicine is and aims to reduce symptoms. Some people will get the active drug, others a dummy pill.
Systemic Lupus ErythematosusBosnia and Herzegovina - RecruitingPHASE3
Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor
This study is testing a medicine called OCTAPLEX for people experiencing serious bleeding while taking a specific type of blood thinner (Factor Xa inhibitor). Researchers want to see if OCTAPLEX can effectively stop the bleeding and if it's safe, comparing two different doses.
Acute Major BleedingBosnia and Herzegovina - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
This study looks at the long-term safety and effectiveness of a medicine called Upadacitinib for people with ulcerative colitis. It's for those who haven't fully responded to previous treatment or have completed an earlier study.
Ulcerative Colitis (UC)Bosnia and Herzegovina - Active not recruitingPHASE3
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
This study is testing a new tablet, IMU-838, for people aged 18-55 with a type of multiple sclerosis (MS) called relapsing MS. It wants to see how well it works, if it's safe, and if people can tolerate it compared to a dummy tablet.
Multiple Sclerosis, Relapsing-RemittingBosnia and Herzegovina - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's DiseaseBosnia and Herzegovina - Active not recruitingPHASE2, PHASE3
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for adults with moderately to severely active Crohn's disease. Researchers want to see how well it works and if it's safe compared to other treatments or a dummy medicine.
Crohn's DiseaseBosnia and Herzegovina - Active not recruitingPHASE3
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
This study looks at a medicine called ocrelizumab for people with progressive multiple sclerosis (PMS). It aims to see how well it works and if it's safe. Everyone in the study will receive the medicine, and doctors will watch their progress closely.
Progressive Multiple Sclerosis (PMS)Bosnia and Herzegovina - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's DiseaseBosnia and Herzegovina - Active not recruitingPHASE3
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
This study compares a new drug, SB27, with an existing one, Keytruda, for advanced lung cancer. Both are given with chemotherapy. Researchers want to see if SB27 works as well as Keytruda for patients with non-small cell lung cancer that has spread.
Non-small Cell Lung Cancer Stage IVBosnia and Herzegovina - Active not recruitingPHASE1
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
This study compares a new medicine called GME751 to an existing treatment, Keytruda, for people with melanoma that has been removed by surgery. It checks if GME751 works similarly and is safe.
MelanomaBosnia and Herzegovina - RecruitingPHASE2
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine called MORF-057 for adults with moderate to severe Crohn's disease. It compares different doses of the medicine to a dummy pill to see if it's safe and helps improve symptoms.
Inflammatory Bowel DiseasesCrohn's DiseaseBosnia and Herzegovina - RecruitingPHASE2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
This study is testing new long-acting medicines for adults with moderate to severe ulcerative colitis. It aims to see how well they work and if they are safe, both on their own and in combinations, compared to a dummy treatment.
Ulcerative ColitisInflammatory Bowel DiseasesColitisColitis, UlcerativeBosnia and Herzegovina - Active not recruitingPHASE3
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
This study is looking at a new medicine called guselkumab for people with psoriatic arthritis. It aims to see how well it reduces pain, swelling, and other symptoms compared to a dummy treatment, and if it helps improve their condition.
Arthritis, PsoriaticBosnia and Herzegovina - Active not recruitingPHASE3
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
This study compares a new drug, alectinib, with standard chemotherapy for people with a certain type of lung cancer (ALK-positive non-small cell lung cancer) after surgery. We want to see if alectinib is better at stopping the cancer from coming back and if it's safe.
Carcinoma, Non-Small-Cell LungBosnia and Herzegovina - Active not recruitingPHASE3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.
Rheumatoid ArthritisBosnia and Herzegovina